# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate ...
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inn...
Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp O...
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inno...